Literature DB >> 8098881

Synergism between the CD3 antigen- and CD2 antigen-derived signals. Exploration at the level of induction of DNA-binding proteins and characterization of the inhibitory activity of cyclosporine.

P K Sehajpal1, V K Sharma, E Ingulli, K H Stenzel, M Suthanthiran.   

Abstract

We have demonstrated earlier that the crosslinkage of the CD3/TCR complex with the CD2 antigen results in the proliferation of normal human T cells. The effect of this synergism was perceptible at the level of induction of the IL-2 gene, a process critical for T cell growth. To further understand the molecular and nuclear basis for this synergism, we have explored the induction of DNA-binding proteins in highly purified normal human T cells signaled via the CD3 and/or CD2 proteins. The effect of transmembrane signaling of T cells with ionomycin, and/or sn-1,2 dioctanoyl glycerol, was also determined. The emergence of nuclear binding proteins was investigated using interleukin-2 sequence specific oligonucleotide probes in the electrophoretic mobility shift assay. Our studies demonstrate for the first time that CD3 antigen-derived signals and CD2 antigen-derived signals are synergistic in inducing the emergence of transcription factors that bind to the NF-AT1, AP-1, and NF-kB sites located in the promoter/enhancer region of the IL-2 gene. Moreover, cyclosporine, at concentrations readily accomplished in clinical practice, was found to inhibit the emergence of these DNA-binding proteins in normal human T cells signaled via cell surface proteins implicated in antigen-dependent T cell activation and in T cells stimulated by mobilization of cellular calcium and activation of protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098881     DOI: 10.1097/00007890-199305000-00035

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects.

Authors:  Yong Zeng; Yi-jing He; Fu-yuan He; Lan Fan; Hong-hao Zhou
Journal:  Acta Pharmacol Sin       Date:  2009-04       Impact factor: 6.150

Review 2.  Immunosuppressive drug therapy.

Authors:  Choli Hartono; Thangamani Muthukumar; Manikkam Suthanthiran
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.